Treatment (Tx) guidelines for skin and mucosal events in patients with solid tumors (pts) receiving TH‐302, a tumor selective, hypoxia‐activated prodrug.

e13616 Background: TH‐302 is essentially inactive in normoxic conditions and is activated in regions of severe hypoxia (<1% O2 saturation), releasing a bromo‐isophosphoramide mustard that alkylates...